Clover Health Investments, Corp. — Form 8-K Summary
Business Context and Reporting Period
Clover Health Investments, Corp. reported the results of its 2022 Annual Meeting of Stockholders, held virtually on September 22, 2022. The filing was signed and submitted on September 23, 2022. Class A and Class B common stock voted together, with Class A holders receiving one vote per share and Class B holders receiving ten votes per share as of the August 2, 2022 record date.
Financial and Operating Metrics
This Form 8-K does not report revenue, profit, cash flow, margins, debt, liquidity, or other financial performance metrics. The filing text does not provide a clear value for any such measure.
Material Changes and Meeting Results
- Director elections: Lee A. Shapiro and William Robinson, Jr. were elected as Class I directors, serving until the 2025 annual meeting and until their successors are elected and qualified.
- Lee A. Shapiro received 920,941,345 votes for, 22,091,756 withheld, and 140,002,057 broker non-votes.
- William Robinson, Jr. received 928,236,387 votes for, 14,796,714 withheld, and 140,002,057 broker non-votes.
- Say-on-frequency vote: Stockholders approved holding future non-binding advisory votes on named executive officer compensation every one year. Clover stated that it will follow this annual frequency until the next required frequency vote.
- The frequency proposal received 940,540,779 votes for one year, 617,597 for two years, 757,053 for three years, 1,117,672 abstentions, and 140,002,057 broker non-votes.
- Auditor ratification: Stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022, with 1,078,668,100 votes for, 3,991,054 against, and 376,004 abstentions.
Guidance, Outlook, Risks, and Unusual Items
The filing contains no financial guidance, operating outlook, management discussion, risk-factor update, contingency disclosure, or unusual accounting item. Its principal governance developments are the election of two directors, adoption of an annual say-on-pay frequency, and auditor ratification.
Investor Verification Checklist
- Verify the elected directors’ committee assignments, independence status, and relevant biographies in subsequent filings.
- Confirm that Clover implements annual advisory compensation votes and review the next proxy statement for the related proposal.
- Review subsequent filings for any changes involving Ernst & Young LLP or the company’s fiscal-year 2022 audit.
- Refer to Clover’s periodic reports for financial performance, liquidity, debt, guidance, and risk information not included in this 8-K.